New! View global litigation for patent families

CA2378613A1 - Selective iglur5 receptor antagonists for the treatment of migraine - Google Patents

Selective iglur5 receptor antagonists for the treatment of migraine

Info

Publication number
CA2378613A1
CA2378613A1 CA 2378613 CA2378613A CA2378613A1 CA 2378613 A1 CA2378613 A1 CA 2378613A1 CA 2378613 CA2378613 CA 2378613 CA 2378613 A CA2378613 A CA 2378613A CA 2378613 A1 CA2378613 A1 CA 2378613A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
receptor
selective
antagonists
invention
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2378613
Other languages
French (fr)
Other versions
CA2378613C (en )
Inventor
David Bleakman
Sandra Ann Filla
Kirk Willis Johnson
Paul Leslie Ornstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd (GB)
Original Assignee
Eli Lilly And Company
David Bleakman
Chappell, Amy Suzon
Sandra Ann Filla
Kirk Willis Johnson
Paul Leslie Ornstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Abstract

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
CA 2378613 1999-07-06 2000-06-27 Selective iglur5 receptor antagonists for the treatment of migraine Expired - Fee Related CA2378613C (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US14248599 true 1999-07-06 1999-07-06
US60/142,485 1999-07-06
US15116599 true 1999-08-27 1999-08-27
US60/151,165 1999-08-27
PCT/US2000/016297 WO2001001972A3 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (2)

Publication Number Publication Date
CA2378613A1 true true CA2378613A1 (en) 2001-01-11
CA2378613C CA2378613C (en) 2007-10-02

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2378613 Expired - Fee Related CA2378613C (en) 1999-07-06 2000-06-27 Selective iglur5 receptor antagonists for the treatment of migraine

Country Status (9)

Country Link
US (4) US6566370B1 (en)
EP (1) EP1200073B1 (en)
JP (1) JP4619595B2 (en)
CN (1) CN1230174C (en)
CA (1) CA2378613C (en)
DE (2) DE60032905D1 (en)
DK (1) DK1200073T3 (en)
ES (1) ES2278619T3 (en)
WO (1) WO2001001972A3 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257545A1 (en) 1999-12-22 2002-11-20 Eli Lilly And Company SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
CN1484642A (en) * 2001-01-05 2004-03-24 伊莱利利公司 Excitatory amino acid receptor antagonists
US6953805B2 (en) * 2001-01-05 2005-10-11 Eli Lilly And Company Excitatory amino acid receptor antagonists
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053139A8 (en) * 2001-01-05 2003-11-13 Kirk Willis Johnson Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053556A3 (en) * 2001-01-05 2003-02-13 Thomas John Bleisch Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
DE60134427D1 (en) * 2001-01-05 2008-07-24 Lilly Co Eli Excitatory amino acid receptor-antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
JP2005529892A (en) 2002-04-26 2005-10-06 イーライ・リリー・アンド・カンパニーEli Lilly And Company Ester prodrugs decahydroisoquinoline-3-carboxylic acid as analgesics
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
DK2061465T3 (en) 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivatives of 4- (N-azacycloalkyl) anilides as potassium channel
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ES2375417T3 (en) 2006-11-28 2012-02-29 Valeant Pharmaceuticals International 1,4-diamino bicyclic analogs of retigabine as modulators of the potassium channels.
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
WO1998045270A1 (en) * 1997-04-07 1998-10-15 Eli Lilly And Company Pharmacological agents
DE60002733D1 (en) * 1999-07-06 2003-06-18 Lilly Co Eli Diester prodrugs of decahydroischinoline-3-carboxylic acid

Also Published As

Publication number Publication date Type
US20040192722A1 (en) 2004-09-30 application
JP2003503449A (en) 2003-01-28 application
EP1200073B1 (en) 2007-01-10 grant
US6566370B1 (en) 2003-05-20 grant
DE60032905D1 (en) 2007-02-22 grant
CA2378613C (en) 2007-10-02 grant
US6855823B2 (en) 2005-02-15 grant
WO2001001972A3 (en) 2001-12-06 application
WO2001001972A2 (en) 2001-01-11 application
DK1200073T3 (en) 2007-05-07 grant
EP1200073A2 (en) 2002-05-02 application
US7157582B2 (en) 2007-01-02 grant
ES2278619T3 (en) 2007-08-16 grant
CN1230174C (en) 2005-12-07 grant
DE60032905T2 (en) 2007-10-18 grant
US20030199546A1 (en) 2003-10-23 application
US20050159445A1 (en) 2005-07-21 application
JP4619595B2 (en) 2011-01-26 grant
CN1359289A (en) 2002-07-17 application
US6759418B2 (en) 2004-07-06 grant

Similar Documents

Publication Publication Date Title
WO1998052611A1 (en) Medicinal composition for prevention or treatment of hepatopathy
WO2000051561A1 (en) Cosmetics
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
WO2004067002A3 (en) SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
CA2361364A1 (en) Dalda analogs and their use
CA2500113A1 (en) Therapeutic piperazine compounds
WO1999002524A1 (en) Antifungal triazole compounds
WO2001010846A3 (en) 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
WO1999044639A1 (en) Remedies for brain infarction
WO2004005286A3 (en) Viral inhibitors
WO1999048528A1 (en) Vascularization inhibitors
WO2002053187A3 (en) Methods and transdermal compositions for pain relief
WO2003051838A3 (en) Protein kinase inhibitors
WO2002030464A1 (en) Novel drugs for liver diseases
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
WO2001032130A3 (en) Phenyl amine carboxylic acid compounds and compositions for delivering active agents
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2001034143A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
WO2002020466B1 (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
CA2421120A1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
WO2002096889A1 (en) Quinazolinone compound and method of preparation and use thereof in preparing anticancerous medicament
WO1997025985A1 (en) Tracheal smooth muscle relaxant
WO2001001973A8 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
WO2000007979A3 (en) Compounds and compositions for delivering active agents
WO2002094320A1 (en) Therapeutic compositions for repairing chondropathy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed